Out of Africa: Complete and partial remissions as a combined outcome in patients with idiopathic membranous glomerulonephritis in Cape Town
- PMID: 26706191
- DOI: 10.1111/nep.12703
Out of Africa: Complete and partial remissions as a combined outcome in patients with idiopathic membranous glomerulonephritis in Cape Town
Abstract
Aim: Remission outcomes among patients with idiopathic membranous glomerulonephritis is unknown in Africa. We sought to determine remission outcomes in a cohort of South African adult patients with IMGN.
Methods: This was a retrospective review of patients with biopsy-proven IMGN over a 10 year period. Secondary causes of MN were excluded. Demographic, clinical, biochemical and histological records were retrieved for analysis. The trends in biochemical parameters from baseline were determined. The primary outcome was the attainment of a complete or partial remission (CR / PR) at the last follow-up.
Results: Fifty-six patients met the criteria for inclusion and 43 had subsequent follow-up care with a median duration of follow-up of 23.0 (13.0-48.0) months. Sixteen patients (37.2%) were treated with immunosuppression (corticosteroids and cyclophosphamide) and 81.4% received anti-proteinuric agents. There were no significant differences in demographic and clinical features of patients categorized by immunosuppression (ISP) use. Changes in level of proteinuria and estimated glomerular filtration rate (eGFR) were also not significantly different between the two groups. Eighteen patients (41.9%) reached CR or PR at the last visit. The median times-to-remission of patients according to ISP status were similar at 48.6 and 48.7 months respectively (P = 0.104) while the proportions of patients not reaching CR/PR at 12 and 24 months were 94.6% and 80.8% respectively. Gender and race did not predict remission status (P > 0.05). Predictors of CR/PR at last visit were eGFR [OR 1.01 (95%CI: 1.00 - 1.02); P = 0.041], and systolic BP (OR 0.97 [95%CI: 0.95 - 0.99); P = 0.036].
Conclusion: Remission outcomes in this African IMGN cohort are delayed and poor.
Keywords: South Africa; immunosuppression; membranous glomerulonephritis; remission.
© 2015 Asian Pacific Society of Nephrology.
Similar articles
-
Urinary N-acetyl-β-glucosaminidase and estimated Glomerular filtration rate may identify patients to be treated with immuno-suppression at diagnosis in idiopathic membranous nephropathy.Nephrology (Carlton). 2018 Feb;23(2):175-182. doi: 10.1111/nep.12952. Nephrology (Carlton). 2018. PMID: 27764902
-
Long-term outcomes of initial therapy for idiopathic membranous nephropathy.Clin Exp Nephrol. 2017 Oct;21(5):842-851. doi: 10.1007/s10157-016-1371-8. Epub 2016 Dec 20. Clin Exp Nephrol. 2017. PMID: 27999961
-
Early initiation of immunosuppressive treatment in membranous nephropathy patients.J Formos Med Assoc. 2017 Apr;116(4):266-275. doi: 10.1016/j.jfma.2017.01.004. Epub 2017 Feb 13. J Formos Med Assoc. 2017. PMID: 28202222
-
New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.Autoimmun Rev. 2016 Jun;15(6):529-38. doi: 10.1016/j.autrev.2016.02.014. Epub 2016 Feb 11. Autoimmun Rev. 2016. PMID: 26876383 Review.
-
Recent advances and prognosis in idiopathic membranous nephropathy.Adv Chronic Kidney Dis. 2012 Mar;19(2):114-9. doi: 10.1053/j.ackd.2012.01.007. Adv Chronic Kidney Dis. 2012. PMID: 22449349 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous